4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

SC 13D/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

SC 13D - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

SC 13D/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

SC 13D - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

SC 13G - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

Announces "Stalking Horse" Agreement for the Sale of Zokinvy® (lonafarnib) Patient Access to Zokinvy® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of Texas. The company also announced a "stalking horse" agreement for the sale of Zokinvy® (lonafarnib) to Sentynl Therapeutics, Inc., a biopharmaceutical company focused on rare diseases. Under the terms of the "stalking horse" agreement, subject to court

Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeriaEiger to receive $500,000 approval milestone payment from AnGesZokinvy approved in the U.S. (2020), 30 European countries (2022), and now Japan (2024)PALO ALTO, Calif., Jan. 18, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchin

PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 11:59 p.m. Eastern Time, on January 5, 2024. The Company's common stock will begin trading on a post-split basis at the market open on January 8, 2024. The Reverse Stock Split is part of the Company's plan to regain compliance with the minimum bid price requireme

Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step

PALO ALTO, Calif., Sept. 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta (CHD). The decision is based on the recommendation of the Data Safety Monitoring Board (DSMB) for the study following its quarterly safety review. In a communication dated September 7, 2023, the DSMB recommended the discontinuation of the LIMT-2 study due to observations of four patients with hepatobiliary events that resulted in liver decompe

PALO ALTO, Calif., Sept. 5, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian, MD, PhD, MBA, CEO of Eiger, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 7:00 AM ET in New York, NY. Eiger will also host one-on-one meetings with investors at the conference. The presentation will be available on the Investors section of the

Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; extends cash runway into Q4 2024David Apelian, MD, PhD, MBA, appointed CEOPALO ALTO, Calif., Aug. 14, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the second quarter 2023 and provided a business update.

Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; extends cash runway to Q4 2024David Apelian, MD, PhD, MBA, appointed CEOLive conference call and webcast at 8:30 am ET todayPALO ALTO, Calif., June 29, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization review, the Company will focus its development effor

Company to host conference call and live webcast on Thursday, June 29, at 8:30 am ETPALO ALTO, Calif., June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization exercise, the company will host a conference call and live webcast on Thursday, June 29, at 8:30 am ET. Conference Call Details The live and replayed webcast of the call will be available through the company's website at

Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting with FDA in Q2Phase 3 HDV LIMT-2 (peginterferon lambda) Study: Complete Randomization in Q2Phase 3 HI AVANT (avexitide) Program: Startup Activities InitiatedCash Position: $75.3 million in Cash, Cash Equivalents, and Short-Term Debt Securities as of March 31, 2023PALO ALTO, Calif., May 11, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for first quarter 2023 and provided a business update.

8-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

8-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

10-K/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

10-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

8-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

NT 10-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

S-8 POS - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

S-8 POS - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

S-8 POS - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

S-8 POS - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)

Citigroup reiterated coverage of Eiger BioPharmaceuticals with a rating of Buy and set a new price target of $27.00 from $26.00 previously

Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step

PALO ALTO, Calif., May 3, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported that, in connection with the appointment of James A. Vollins as General Counsel, Chief Compliance Officer and Corporate Secretary, Eiger granted him a stock option to purchase 120,000 shares of Eiger's common stock. The stock option was approved by the Compensation Committee of Eiger's Board of Directors and granted under the Eiger BioPharmaceuticals, Inc. 2021 Inducement Plan, as amended, with a grant date of April 30, 2023, as an

PALO ALTO, Calif., Jan. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today provided the company's outlook across multiple pipeline programs and operations, including planned 2022 catalysts and milestones. "This is a pivotal year for Eiger as we plan for topline data from the landmark D-LIVR study by year end.  D-LIVR is the largest trial conducted in HDV and if positive will support re

PALO ALTO, Calif., Sept. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Erik Atkisson as the Company's General Counsel and Chief Compliance Officer. Mr. Atkisson brings over twenty years of experience to Eiger, and was most recently Chief Compliance Officer, Legal Counsel, and Privacy Officer at Cytokinetics, Incorporated, where he was responsible for legal matter

PALO ALTO, Calif., April 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Kim Sablich to its Board of Directors.  Ms. Sablich is a pharmaceutical industry veteran with broad commercial experience spanning over two decades in large pharma and biotechnology companies, including vaccines and prescription products across diverse therapeutic areas, and rare and ultra-rare disease programs.  Ms. Sablich is currently Executive Vice President, General Manager, North America at Jazz Pharmaceuticals

Gainers Orgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increased by 6.76% to $3.47. The company's market cap stands at $103.3 million. GRI Bio (NASDAQ:GRI) stock increased by 6.65% to $0.54. NuCana (NASDAQ:NCNA) shares rose 5.92% to $0.25. The market value of their outstanding shares is at $13.4 million. Stoke Therapeutics (NASDAQ:STOK) shares increased by 5.42% to $12.83. The company's market cap stands at $594.0 million. Candel Therapeutics (NASDAQ:CADL) stock moved upwards by 4.99% to $6.72. The market value of their outstanding shares is at $197

Shares of STAAR Surgical Company (NASDAQ:STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3% to $44.30 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares climbed 130.1% to $2.9790. TCBP announced execution of non-binding letter of intent for acquisition of NK Platform Technologies. Allurion Technologies Inc. (NASDAQ:ALUR) gained 70% to $2.8801 after the company announced the commercial availability of its Virtual Care Suite in the United States. Also, Chardan Capital initiated coverage on the stock w

Gainers Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 64.3% to $2.76 during Thursday's regular session. The market value of their outstanding shares is at $80.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 61.38% to $2.1. The market value of their outstanding shares is at $5.0 million. Eiger BioPharmaceuticals (NASDAQ:EIGR) shares moved upwards by 38.18% to $2.28. The company's market cap stands at $3.3 million. Macrogenics (NASDAQ:MGNX) stock rose 32.55% to $18.12. The company's market cap stands at $1.1 billion. Barinthus Biotherapeutics (NASDAQ:BRNS) shares increased by 29.55% to $3.77. The company's market cap stands at $146.7 million. Curis (NASDAQ

Shares of Flora Growth Corp. (NASDAQ:FLGC) fell sharply in today’s pre-market trading after the company reported the launch of proposed underwritten public offering of common shares. Flora Growth shares tumbled 20.2% to $2.13 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers HWH International Inc. (NASDAQ:HWH) rose 175% to $4.32 in pre-market trading. Zhongchao Inc. (NASDAQ:ZCMD) gained 43% to $2.18 in pre-market trading after gaining 22% on Wednesday. Brooge Energy Limited (NASDAQ:BROG) gained 26.4% to $2.39 in pre-market trading after dipping over 20% on Wednesday. Sintx Technologies, Inc. (NASDAQ:SINT) shares rose 23.5% to $0.0284 in pre-ma

- SEC Filing

Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. Kineta (NASDAQ:KA) shares rose 8.46% to $0.58. The company's market cap stands at $6.3 million. Simulations Plus (NASDAQ:SLP) shares increased by 6.74% to $40.99. The market value of their outstanding shares is at $818.4 million. As per the news, the Q2 earnings report came out today. Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 6.66% to $1.44. The company's market cap stands at $54.9 million. Eiger BioPharmaceuticals (NASDAQ:EIGR) shares increased by 6.66% to $1.76. The market value of their outstanding shares is

Shares of Nuvve Holding Corp. (NASDAQ:NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quarter financial results. Nuvve Holding posted a quarterly loss of $6.98 per share, versus market estimates for a loss of $5.60 per share. The company’s sales came in at $1.65 million, compared to expectations of $3.00 million. Nuvve Holding shares dipped 29.6% to $0.7746 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Vast Renewables Limited (NASDAQ:VSTE) shares jumped 179% to $8.62 after jumping 39% on Thursday. CXApp Inc. (NASDAQ:CXAI) gained 151% to $6.15 after the company announced a partnership with Google Clou

Monday, Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) announced that it and its direct subsidiaries have filed voluntary petitions for Chapter 11 protection in the U.S. Bankruptcy Court for the Northern District of Texas. The company also announced a “stalking horse” agreement to sell Zokinvy (lonafarnib) to Sentynl Therapeutics Inc., a biopharmaceutical company focused on rare diseases.  Under the terms of the “stalking horse” agreement, subject to court approval, Sentynl Therapeutics will pay up to $26.0 million, subject to certain purchase price adjustments, including per diem reductions, if the sale closes after April 24, 2024. In accordance with Section 363 of the Bankruptcy Code,

Gainers Sunshine Biopharma (NASDAQ:SBFM) stock rose 86.3% to $0.11 during Monday's regular session. The company's market cap stands at $11.2 million. Xilio Therapeutics (NASDAQ:XLO) stock rose 25.93% to $1.36. The market value of their outstanding shares is at $37.4 million. Akanda (NASDAQ:AKAN) shares moved upwards by 24.35% to $0.14. The company's market cap stands at $1.2 million. Mesoblast (NASDAQ:MESO) shares moved upwards by 20.95% to $6.06. The company's market cap stands at $614.9 million. Brainstorm Cell (NASDAQ:BCLI) shares increased by 18.29% to $0.67. The market value of their outstanding shares is at $32.7 million. The company's, Q4 earnings came out today. Adagene (NASDAQ